Biohaven Ltd. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
BHVN New York 2834 www.biohaven.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Biohaven Ltd.

Biohaven to Present New Clinical Data at ESMO Congress on BHV-1530, a Novel FGFR3-Directed ADC With a Proprietary Topoisomerase I (TopoIx) Payload - Jul 20th, 2026 5:30 am
Bexorg Expands Leadership Team with Appointments of Bruce Car, Ph.D., as Chief Scientific Officer and Michael Fenn, Ph.D., as Chief Business Officer - Jul 13th, 2026 6:00 am
ARPA-H puts $160M into bespoke drug therapies; Biohaven switches up scientific leadership - Jul 10th, 2026 2:04 am
Is Biohaven’s (BHVN) R&D Shake-Up Quietly Redefining Its Late-Stage Pipeline Strategy? - Jul 10th, 2026 12:11 am
Biohaven Announces Scientific Leadership Transitions - Jul 9th, 2026 3:00 pm
Biohaven (BHVN) Completes Enrollment in RISE3 Trial - Jul 9th, 2026 4:40 am
BHVN Stock Builds Momentum Ahead Of Multiple H2 2026 Clinical Data Readouts - Jul 8th, 2026 6:12 pm
Why Wall Street Is Growing More Cautious on Biohaven (BHVN) - Jul 6th, 2026 11:20 am
Biohaven Completes Enrollment in RISE 3 Pivotal Focal Epilepsy Study with Opakalim, a Selective Kv7.2/7.3 Activator - Jun 30th, 2026 5:30 am
Why Is BHVN Stock Falling Premarket? - Jun 30th, 2026 2:19 am
BofA cuts ratings on four biopharma stocks over valuation and catalyst concerns - Jun 29th, 2026 10:01 am
Biohaven Advances a New Class of Precision Immunology Therapies: First MoDE Extracellular Protein Degrader, BHV-1300, Begins Phase 3 Pivotal Trial in Graves' Disease - Jun 29th, 2026 5:30 am
Biohaven (BHVN) Climbs 14% Higher Ahead of New Clinical Trials - Jun 22nd, 2026 7:46 pm
Pfizer (PFE) CFO Dave Denton to Step Down Effective August 15 - Jun 21st, 2026 4:52 am
Pfizer CFO Dave Denton stepping down in August 2026 - Jun 18th, 2026 6:30 am
Pfizer Announces Chief Financial Officer Transition - Jun 18th, 2026 4:45 am
Biohaven (BHVN) Climbs 12.66% Ahead of Pipeline Updates - Jun 17th, 2026 6:02 pm
Rapport ‘fully prepared’ to launch seizure drug solo, CEO says - Jun 12th, 2026 3:31 am
Is Biohaven (BHVN) Quietly Reframing Its Investment Story Around Brain Energy and Precision Immunology? - Jun 8th, 2026 1:10 pm
Biohaven (BHVN) Valuation Check After New R&D Milestones In Immunology Neuroscience And Metabolic Programs - Jun 7th, 2026 3:17 pm